Platelet ADP receptor inhibitors

1. A compound of the following formula:

wherein:

A is thienyl, optionally substituted with from one to two halogen atoms;

W is phenylene, optionally substituted with from one to two substituents selected from the group consisting of halogen, methyl and trifluoromethyl;

E is selected from the group consisting of H, —C 1 -C 8 alkyl, polyhaloalkyl and —C 3-8 -cycloalkyl;

n is an integer from 0-4;

each instance of X 1 , X 2 and X 3 is a member independently selected from the group consisting of hydrogen, halogen, polyhaloalkyl, —OR 3 , —SR 3 , —CN, —NO 2 , —SO 2 R 3 , —CONHR 3 , —C(═NH)NHCH 3 , —C 1-10 -alkyl, —C 3-8 -cycloalkyl, aryl, aryl-substituted by 1-4 R 3 groups, amino, amino-C 1-8 -alkyl, C 1-3 -acylamino, C 1-3 -acylamino-C 1-8 -alkyl, C 1-6 -alkylamino, C 1-6 -alkylamino C 1-8 -alkyl, C 1-6 dialkylamino, C 1-6 dialkylamino C 1-8 -alkyl, C 1-6 -alkoxy, C 1-6 -alkoxy-C 1-6 -alkyl, carboxy-C 1-6 -alkyl, C 1-3 -alkoxycarbonyl, C 1-3 -alkoxycarbonyl-C 1-6 -alkyl, carboxy C 1-6 alkyloxy, hydroxy, hydroxy C 1-6 alkyl, a 5 membered fused pyrrolidino, imidazolo, thiazolo or oxazolo ring and a 5 to 6 membered aromatic or nonaromatic heterocyclic ring selected from the group consisting of oxazolinyl, pyrrolidinyl, imidazolinyl and pyridyl, with proviso that the carbon and nitrogen atoms, when present in the heterocyclic ring, are unsubstituted, mono- or di-substituted independently with 0-2 R 4 groups;

R 3 and R 4 are each independently selected from the group consisting of hydrogen, halogen, —CN, —NO 2 , —C 1-10 alkyl, C 3-8 -cycloalkyl, aryl, amino, amino-C 1-8 -alkyl, C 1-3 -acylamino, C 1-3 -acylamino-C 1-8 -alkyl, C 1-6 -alkylamino, C 1-6 -alkylamino C 1-8 alkyl, C 1-6 dialkylamino C 1-6 dialkylamino C 1-8 alkyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 -alkyl, carboxy-C 1-6 -alkyl, C 1-3 -alkoxycarbonyl, C 1-3 -alkoxycarbonyl-C 1-6 alkyl, carboxy-C 1-6 -alkyloxy, hydroxy, hydroxy-C 1-6 -alkyl, -thio and thio-C 1-6 -alkyl, wherein optionally two alkyl groups attached to a nitrogen atom can be combined with the nitrogen atom to form a pyrrolidinyl, piperidinyl or morpholinyl ring;

Y is selected from the group consisting of O, S, N—OR 5 and NR 5 ;

R 5 is selected from the group consisting of H, C 1-10 alkyl, C 3-8 -cycloalkyl, and CN;

or pharmaceutically acceptable salts.

2. A compound according to claim 1 , wherein

A is selected from the group consisting of:

Y is selected from the group consisting of O, S, N—OR 5 and NR 5 ;

E is selected from the group consisting of H, or C 1-8 ealkyl; and

W is selected from the group consisting of:

3. A compound of claim 1 , selected from the group consisting of:

4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claims 2 - 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6. A method for treating thrombosis in a mammal comprising the step of administering to a mammal a therapeutically effective amount of compound of claim 1 or a pharmaceutically acceptable salt thereof.

7. A method of claim 6 , wherein said mammal is a human.

8. A method of claim 6 , wherein said thrombosis is indicated by at least one selected from the group consisting of acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and protheses.